The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up.

@article{Peters2015TheTO,
  title={The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up.},
  author={Elke Peters and Tobias Anzeneder and Christian Jackisch and Thomas Dimpfl and Georg Kunz and Alexander Katalinic and Annika Waldmann},
  journal={Deutsches Arzteblatt international},
  year={2015},
  volume={112 35-36},
  pages={
          577-84
        }
}
BACKGROUND Breast cancer is the most common cancer in women in Germany. Mortality from breast cancer has declined over the past 15 years, but less so in women aged 70 or older than in younger women. The discrepancy might be explained by age-related differences in treatment. METHODS Data from the Patients' Tumor Bank of Hope (PATH) database of women who underwent adjuvant treatment for the treatment of an invasive primary tumor without distant metastases (year of diagnosis, 2006-2011) were… Expand
Overall survival of elderly patients with breast cancer is not related to breast-cancer specific survival: A single institution experience in Japan.
TLDR
Standard multidisciplinary treatment for breast cancer prevents recurrence and metastasis and tends to extend breast cancer-specific survival even in elderly patients. Expand
Adjuvant chemotherapy in elderly patients with primary breast cancer: are women ≥65 undertreated?
TLDR
Higher recurrence rates compared with younger postmenopausal women suggest that older patients with early stage BC are undertreated, and treatment needs to be adapted to general health and tumor biology rather than age. Expand
Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies.
TLDR
The uptake of trastuzumab therapy varied widely between studies and across subgroups suggesting that there may be some inequalities in the use of this agent, however, the findings should be interpreted with caution due to study heterogeneity and potential confounding. Expand
Long-term Incidence and Mortality Trends for Breast Cancer in Germany
TLDR
The analysis suggests that the introduction of mammography screening contributed to a decrease in the incidence of advanced-stage breast cancers and in breast cancer-related mortality rates but also resulted in a substantial number of overdiagnoses. Expand
Lymph node density in papillary thyroid carcinoma is a prognostic factor after adjusting for pathological stage
TLDR
Results suggest that the lymph node density can be used as a predictor for the survival outcomes after adjustment for the pathological stage in the eighth edition of the Union for International Cancer Control Tumor-Node Metastasis Classification of Malignant Tumors. Expand
The Global Need for a Trastuzumab Biosimilar for Patients With HER2‐Positive Breast Cancer
TLDR
Data suggest that some patient subgroups, including older patients, those with HER2+/hormone receptor‐positive disease, and women with small and/or node‐negative HER2 + tumors, were less likely to receive anti‐HER2 therapy, potentially improving patient outcomes. Expand
Abstract 398: Real-life example of biobanking: results of the PATH Biobank
TLDR
Tumour content depended on clinical conditions and staging (ranging from 34% failure in samples derived from neo adjuvantly treated patients to 2% in cases with staging UICC IV). Expand
Treatment Quality in Breast Cancer
in this issue of Deutsches Ärzte blatt International Germany has fallen less than the rate in younger women (4). There are various possible reasons for this, such as younger patients’ better accessExpand
Is There an Age Threshold for Holding Off on Testing Novel Therapies?
TLDR
Clinical trials assessing novel anticancer therapies such as targeted therapies or immune checkpoint inhibitors should be developed in elderly patients regardless of age as these therapies may present a favorable benefit-risk profile compared to chemotherapy which is often more toxic and at risk of geriatric deconditioning. Expand
Langfristige Inzidenz- und Mortalitätstrends für Brustkrebs in Deutschland
Einleitung Änderungen bei den Risikofaktoren und das 2005 eingeführte Mammografiescreening bedingen eine hohe Dynamik der brustkrebsassoziierten Krankheitslast in Deutschland. Ziel der Studie istExpand
...
1
2
...